文献速递复苏、休克与脓毒症

碳酸氢钠与无脉性电活动及无收缩性院外心脏骤停生存改善相关

Sodium bicarbonate administration is associated with improved survival in asystolic and PEA Out-of-Hospital cardiac arrest.
PubMed 文献 · Resuscitation · 2022-11-18
一句话结论观察性数据显示,碳酸氢钠与无收缩性心律和无脉性电活动(PEA)院外心脏骤停的生存改善相关,尤其无收缩性心律的ROSC更高,需前瞻性随机研究证实。

该研究基于2019-2020年ESO数据协作组院前电子健康记录数据库,涵盖50个州1322家机构,纳入复苏持续5-40分钟的非创伤性院外心脏骤停(OHCA)记录23567条,其中6663条(28.3%)接受碳酸氢钠。按初始心电图心律分层(无收缩性心律67.4%、PEA 16.6%、VF/VT 15.1%),采用倾向性评分匹配及校正/未校正逻辑回归比较碳酸氢钠与未用碳酸氢钠组的院前ROSC和出院生存。倾向匹配队列中,无收缩性心律组碳酸氢钠组ROSC更高(10.6% vs 8.8%,p=0.013),PEA和VF/VT组无差异;无收缩性心律组生存更高(3.3% vs 2.4%,p=0.020),PEA组生存更高(8.1% vs 5.4%,p=0.034),VF/VT组无差异。校正/未校正回归结果一致:无收缩性心律组碳酸氢钠与ROSC相关(uOR 1.23,95%CI 1.04-1.44)及生存相关(uOR 1.40,95%CI 1.05-1.87),PEA组与生存相关(uOR 1.54,95%CI 1.03-2.31)。作者结论认为碳酸氢钠与不可除颤心律生存及无收缩性心律ROSC相关,需前瞻性随机研究证实。

要点

  • 倾向匹配队列中,无收缩性心律组碳酸氢钠组ROSC 10.6% vs 对照组8.8%(p=0.013),PEA和VF/VT组ROSC无差异。
  • 无收缩性心律组出院生存:碳酸氢钠组3.3% vs 对照组2.4%(p=0.020);PEA组8.1% vs 5.4%(p=0.034);VF/VT组无差异。
  • 校正/未校正逻辑回归一致:无收缩性心律组碳酸氢钠与ROSC相关(uOR 1.23,95%CI 1.04-1.44)及生存相关(uOR 1.40,95%CI 1.05-1.87)。
  • PEA组碳酸氢钠与生存相关(uOR 1.54,95%CI 1.03-2.31)。
  • 作者认为该观察性研究结果需前瞻性随机研究证实。

适用人群与场景

  • 2019-2020年ESO数据协作组院前电子健康记录数据库中,50个州1322家机构的非创伤性院外心脏骤停(OHCA)患者。
  • 纳入复苏持续时间5-40分钟的OHCA记录,按初始心电图心律分层:无收缩性心律、PEA、VF/VT。

研究设计与关键结果

  • 研究类型为基于院前电子健康记录数据库的观察性研究,共分析23567条记录,其中6663条(28.3%)接受碳酸氢钠。
  • 初始心律构成:无收缩性心律67.4%,PEA 16.6%,VF/VT 15.1%。
  • 倾向匹配队列中,无收缩性心律组ROSC:碳酸氢钠组10.6% vs 对照组8.8%(p=0.013);PEA和VF/VT组ROSC无差异。
  • 倾向匹配队列中,无收缩性心律组出院生存:碳酸氢钠组3.3% vs 对照组2.4%(p=0.020);PEA组8.1% vs 5.4%(p=0.034);VF/VT组无差异。
  • 校正/未校正逻辑回归结果一致:无收缩性心律组碳酸氢钠与ROSC相关(uOR 1.23,95%CI 1.04-1.44),与生存相关(uOR 1.40,95%CI 1.05-1.87);PEA组与生存相关(uOR 1.54,95%CI 1.03-2.31)。

证据类型、等级与局限

  • 证据类型:基于院前电子健康记录数据库的观察性研究。
  • 局限:作者指出该研究为观察性研究,研究结果需前瞻性随机研究证实。

对床旁实践的改变

  • 作者认为碳酸氢钠与不可除颤心律(无收缩性心律和PEA)的生存改善相关,与无收缩性心律的ROSC改善相关;该观察性研究结果需前瞻性随机研究证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sodium bicarbonate ("bicarb") administration in out-of-hospital cardiac arrest (OHCA) is intended to counteract acidosis, although there is limited clinical evidence to support its routine administration. We sought to analyze the association of bicarb with resuscitation outcomes in non-traumatic OHCA.

METHODS: Records were obtained from the 2019-2020 ESO Data Collaborative prehospital electronic health record database, spanning 1,322 agencies in 50 states. OHCAs with resuscitations lasting 5-40 minutes were stratified by presenting ECG rhythm (VF/VT, pulseless electrical activity (PEA), asystole) for analysis. The outcomes of any prehospital ROSC and survival to discharge were compared by bicarb status using propensity score matching and logistic regressions with/without adjustment.

RESULTS: We analyzed 23,567 records, 6,663 (28.3 %) of which included bicarb administration. Most patients presented in asystole (67.4 %), followed by PEA (16.6 %), and VF/VT (15.1 %). In the propensity-matched cohort, ROSC was higher in the bicarb group for the asystole group (bicarb 10.6 % vs control 8.8 %; p = 0.013), without differences in the PEA or VF/VT groups. Survival was higher in the bicarb group for asystole (bicarb 3.3 % vs control 2.4 %; p = 0.020) and for PEA (bicarb 8.1 % vs control 5.4 %; p = 0.034), without differences in the VF/VT group. These results were consistent across adjusted/unadjusted logistic regression analyses: bicarb was associated with ROSC and survival in asystole [uOR (95 % CI): ROSC 1.23 (1.04-1.44), survival 1.40 (1.05-1.87)] and with survival in PEA (1.54 (1.03-2.31).

CONCLUSIONS: Bicarb was associated with survival in non-shockable rhythms and ROSC in asystole. Findings from this observational study should be corroborated with prospective randomized work.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Niederberger SM, Crowe RP, Salcido DD, et al. Sodium bicarbonate administration is associated with improved survival in asystolic and PEA Out-of-Hospital cardiac arrest. Resuscitation. 2022. PMID: 36403821. doi:10.1016/j.resuscitation.2022.11.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。